Semaglutide Shows Promise for Liver Health in Obese Adolescents
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a significant health concern affecting 30%-40% of youth with obesity. This condition can lead to severe liver damage, including fibrosis and cirrhosis. Currently, there are no approved pharmacologic therapies for MASLD in this vulnerable pediatric population, leaving a critical gap in treatment options for affected adolescents.
Study Design
This was a single-center retrospective case series conducted at a tertiary care children's hospital. Researchers evaluated five adolescents (mean age: 17.0 years, 60% male, 100% Hispanic) with obesity and suspected MASLD. Participants had a high mean body mass index (BMI) of 50.8 kg/m² at baseline. All subjects were treated with semaglutide for at least 3 months as part of their clinical care, with no specific dose in mg/kg provided in the abstract.
Results
The study observed significant improvements in key liver biomarkers after semaglutide treatment. Baseline mean alanine aminotransferase (ALT), an indicator of liver inflammation, was 107.4 ± 26.8 IU/L, which significantly decreased to 69.0 ± 17.9 IU/L (p<0.01). Similarly, aspartate aminotransferase (AST) levels dropped from 64.6 ± 16.2 IU/L at baseline to 43.6 ± 8.8 IU/L (p<0.01). These reductions indicate a decrease in hepatic inflammation. The most important finding was a statistically significant reduction in the AST to platelet ratio index (APRI), a non-invasive marker for liver fibrosis, from 0.41 ± 0.07 at baseline to 0.28 ± 0.05 (p=0.01). This represents a substantial improvement in indicators of both hepatic inflammation and potential fibrosis in these high-risk adolescents.
Key Findings
- Mean alanine aminotransferase (ALT) levels, a marker of liver inflammation, significantly decreased from 107.4 IU/L to 69.0 IU/L (p<0.01) after semaglutide treatment.
- Mean aspartate aminotransferase (AST) levels also showed a significant reduction from 64.6 IU/L to 43.6 IU/L (p<0.01), further indicating reduced hepatic inflammation.
- The AST to platelet ratio index (APRI), a non-invasive marker for liver fibrosis, significantly improved from 0.41 at baseline to 0.28 (p=0.01), suggesting a positive impact on liver scarring.
- All five adolescents treated with semaglutide for at least 3 months showed improvements in liver biomarkers, despite their high mean BMI of 50.8 kg/m².
Why It Matters
These preliminary findings are highly significant as they suggest semaglutide could be a viable pharmacologic option for adolescents battling MASLD, a condition currently lacking approved treatments. The observed improvements in liver enzymes and fibrosis markers highlight its potential to mitigate liver damage and prevent progression to more severe disease. This could pave the way for semaglutide to become the first approved drug therapy for MASLD in pediatric populations, offering a much-needed intervention. Larger, prospective studies, potentially Phase II or III human trials, are crucial to confirm these promising early signals and move towards clinical implementation.
semaglutide
MASLD
obesity
adolescents
case series
GLP-1 agonist